Table 1.
Clinical information, pathologic results and radiologic features of 6 patients.
| Variable | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | |
|---|---|---|---|---|---|---|---|
| Patient factors | |||||||
| Sex | F | F | F | F | F | F | |
| Age | 61 | 75 | 71 | 73 | 62 | 61 | |
| Axillary LAP-related symptoms and signs | None | None | None | None | None | None | |
| Prior breast cancer characters | |||||||
| Cancer type | IDC | IDC | IDC | DCIS | IDC | IDC | |
| Cancer subtype | ER-/PR-/HER2+ | ER+/PR+/HER2- | ER+/PR+/HER2+ | NA⁎⁎ | TN | ER+/PR-/HER2- | |
| TNM stage | pT1N1 | pT1cN0 | pT1N0 | pTisN0 | ypT0N0† | T1cN1 | |
| Tumor location | UOQ | UIQ | UIQ | UOQ | UOQ | Central | |
| COVID-19 vaccine types and intervals | |||||||
| 1st dose | Vaxzevria | PBV | Vaxzevria | Vaxzevria | Vaxzevria | Vaxzevria | |
| 2nd dose | Not yet | PVB | Not yet | PVB | Not yet | Not yet | |
| Interval between US detection of LAP and last COVID-19 administration (days) | 22 | 19 | 14 | 28 | 21 | 26 | |
| Side of vaccination/axillary LAP/prior breast cancer | L/L/R | L/L/R | R/R/L | L/L/R | L/L/R | R/R/L | |
| Radiologic features of LAP | |||||||
| Round shape | No | Yes | No | Yes | No | No | |
| Irregular margins | No | No | No | No | No | No | |
| MCT ≥ 3mm on US (mean, mm)‡ | Yes (3.35) | Yes (5.38) | Yes (3.0) | Yes (6.4) | Yes (4.0) | Yes (3.08) | |
| L/W < 1.5 on CT and/or MRI (mean)‡§ | Yes (1.43) | Yes (1.3) | Yes (1.09) | Yes (1.3)‖ | Yes (1.32) | No (1.6) | |
| IMCT ≥ 2X on CT and/or MRI (mean, time)‡¶ | Yes (3.75) | Yes (3.4) | Yes (2.19) | Yes (2.9)‖ | Yes (2.91) | No (1.7) | |
| Involved axillary level | Level I | Level I and II | Level I | Level I | Level 1 | Level I | |
| Axillary level | Multiple | Multiple | Single | Multiple | Multiple | Single | |
| US-guided biopsy results of LAP | Benign | Benign | Benign | NA†† | NA †† | NA†† | |
CT = computed tomography; DCIS = ductal carcinoma in situ; ER = estrogen-receptor; F = female; HER2 = human epidermal growth factor receptor 2; IDC = invasive ductal carcinoma; IMCT = interval change in maximum cortical thickening; L = left; LAP = lymphadenopathy; L/W = Length to width; MCT = maximum cortical thickness; MRI = magnetic resonance imaging; NA = not applicable; PBV = Pfizer-BioNTech COVID-19 vaccine; PR = progesterone-receptor; R = right; TN = triple negative; UIQ = upper-inner quadrant; UOQ = upper-outer quadrant; US = ultrasound.
Clinical stage before NAC was cT2N2.
Mean value if multiple.
Lowest number among values on CT or MRI or both.
Highest number among values on CT or MRI or both.
Values from US only as no CT and MRI scans available.
Limited medical record from outside hospital.
Short-term follow-ups were recommended instead of biopsy.